DMP (disease management programme) triumph for Germany's Schmidt
This article was originally published in Clinica
Executive Summary
The signing of the first German disease management programme (DMP) last week must be seen as a triumph for health minister Ulla Schmidt, recently confirmed in her post in Chancellor Gerhard Schroder's new cabinet. Despite opposition from the doctors association and the German hospitals association (DKG) (see this issue, p 5), the North Rhineland association of statutory health insurance physicians (KVN) entered into contracts with seven sickness funds to provide optimum care for breast cancer sufferers.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.